Related Experiment Video
Updated: Apr 16, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
7.5K
Relationship between programmed cell death-1 polymorphisms and clearance of hepatitis B virus
Y Ülger1, S Bayram2, M Ü Sandıkçı1
1Department of Gastroenterology, Faculty of Medicine, Çukurova University, Adana, Turkey.
International Journal of Immunogenetics
|March 5, 2015
Summary
This study found no significant link between Programmed Cell Death-1 (PD-1) gene variations and chronic Hepatitis B virus (HBV) infection susceptibility. Further research is needed to confirm these findings in diverse populations.
Area of Science:
- Immunology
- Genetics
- Hepatology
Background:
- Programmed Cell Death-1 (PD-1) is crucial for regulating T-cell responses in Hepatitis B virus (HBV) infection.
- Genetic variations in the PD-1 gene may influence susceptibility to chronic HBV infection.
Purpose of the Study:
- To investigate the association between PD-1 gene polymorphisms and the risk of developing chronic HBV infection.
- To analyze single nucleotide polymorphisms (SNPs) at positions +7146 G>A and +7209 C>T in the PD-1 gene.
Main Methods:
- A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was employed.
- Genotype distributions were analyzed in 220 chronic HBV patients and 165 individuals who spontaneously cleared HBV.
Main Results:
- No statistically significant differences in genotype distributions for PD-1 +7146 G>A and +7209 C>T polymorphisms were observed between chronic HBV and spontaneous clearance groups.
- A borderline significant association was noted between the PD-1 +7146 GA genotype and HBV chronicity risk in males (OR = 1.88, P = 0.07).
Conclusions:
- The studied PD-1 gene polymorphisms (+7146 G>A and +7209 C>T) do not appear to play a major role in genetic susceptibility to chronic HBV infection in the studied population.
- Larger, ethnically diverse studies are required to validate these findings and explore potential gender-specific effects.
More Related Videos
Related Concept Videos
01:25Hepatitis
63
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
358
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
263
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
78
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
78
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72